Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $41.90 -0.29%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
COHR, LVWD, FWDI, More
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
COHR, LVWD, FWDI, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $1.15 million versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AEVEX Corp. (AVEX) Reports Q2 EPS of $0.01; offers guidance
- Cerebras Systems Inc. (CBRS) Misses Q2 EPS by $2.80, Misses on Revenue; Offers FY26 Revenue Guidance
- StubHub Holdings, Inc. (STUB) Misses Q2 EPS by 24c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
